News

One of the fastest growing physical therapy providers in the region, Mountain River Physical Therapy chose Clinicient’s integrated solution to increase therapist efficiency and access the advanced reporting

In Europe, Resolor is approved for use in women, and so the new variation extends the use of this treatment to male patients. It is estimated that about

Manufactured by 3M Drug Delivery Systems, it is claimed to be the first bioequivalent alternative for GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate). It can be used for the

Produced using the patented Microcyn® Technology, The Alevicyn SG prescription product, under the supervision of a healthcare professional, is indicated to manage and relieve the burning, itching and

With the submission, the company looks to treat multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an

The trial includes an investigational therapy for patients with refractory aggressive non-Hodgkin’s lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified

Both conditions are rare genetic disorders of obesity associated with defects in the MC4 signaling pathway. Phase 2 Trial in Prader-Willi Syndrome (PWS) The first Phase 2 trial

The FDA’s joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee have voted 18 to 6 vote

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. It inhibits a distinct profile of angiogenic tyrosine kinase